oncologic

Acquire the knowledge and skills necessary to diagnose and treat patients with hematological and oncologic diseases

Pediatric Hematology/Oncology Fellowship 2010

Xgeva was reviewed Wednesday by the FDA's oncologic drugs advisory committee which is made up of non-FDA medical experts.

FDA Panel Votes Against Expanding Use of Amgen Drug Xgeva Jennifer Corbett Dooren 2012

Unfortunately, the cost of oncologic care has never declined, and the pricing of new therapies with biomarkers genetic indicators of who is likely to benefit from the therapy is at record levels.

Getting Real About Cancer Care and Medical Resources 2011

While the clinic primarily sees children with oncologic diagnoses, other patients with life-threatening diseases are seen as well (active patients involved with PACT).

Pediatric Palliative Care Fellowship Curriculum 2010

Acquire a fund of knowledge and skills necessary to diagnose and treat patients with hematological and oncologic diseases

Pediatric Hematology/Oncology Fellowship 2010

The subterfuge was so extensive that when they brought in an oncologic surgeon from Memorial Sloan Kettering to perform a radical hysterectomy, he never met his famous patient until she was asleep under anesthesia, and Eva never knew that her surgeon was anyone other than her own doctor.

Eva Peron, Cervical Cancer and the Pap Smear aka TBTAM 2008

: Develops oncologic and immunologic antibody therapeutics Stock-Market Value

13D Filings 2009

OBJECTIVE: To evaluate the appropriateness of recommendations for hysterectomies done for nonemergency and non-oncologic indications.

In Defense of the Hysterectomy aka TBTAM 2007

The agency also convened an oncologic drugs advisory committee meeting where one attending physician, after reviewing the evidence, expressed concern that the drugs might be "Miracle-Gro for cancer."

Merrill Goozner: What Happens When a Heavily-Advertised Drug Harms? 2008

In a 16-0 vote, the FDA's oncologic drugs advisory committee concluded clinical studies of Glaxo's Promacta demonstrated a favorable risk-benefit profile for its use in short-term treatment of people with chronic immune thrombocytopenic purpura, or ITP, which involves low platelet counts and spontaneous bleeding.

FDA Panel Backs Glaxo Platelet Drug Promacta 2008